Human CXCL10 (IP-10) ELISA

Catalog Number:
DIY2097H
Availability:
In stock
Application:
ELISA
100% Homology:
Homo sapiens (human), Hylobates moloch (silvery gibbon), orilla gorilla gorilla (western lowland gorilla), Pan paniscus (pygmy chimpanzee), Pan troglodytes (chimpanzee)

Components

UsageQuantityComponentSize
Detection Antibody50 µgKPB1265Y-050
Standard5 µgRP0871H-005
Capture Antibody100 µgKP1264Y-1001 Pack (<= 10 Plates)
Capture Antibody100 µg X 2KP1264Y-1001 Pack (<= 20 Plates)
  • The Human CXCL10 (C-X-C motif chemokine ligand 10, also known as IP-10) ELISA is designed for the quantitative measurement of CXCL10 in human cell culture supernatants and can also be used to measure CXCL10 in additional biological sample types reported in the literature, including serum, plasma, cerebrospinal fluid (CSF), bronchoalveolar lavage (BAL) fluid, urine, and tissue lysates, with minor protocol modifications recommended to optimize performance across different matrices. CXCL10 is an interferon-inducible CXC chemokine produced primarily by monocytes, macrophages, endothelial cells, fibroblasts, and epithelial cells in response to interferon-γ (IFN-γ) and type I interferons, and it functions through the CXCR3 receptor to recruit activated T lymphocytes, NK cells, and other immune effector cells to sites of inflammation. In healthy individuals, circulating CXCL10 levels are typically low (often <50-100 pg/mL in serum or plasma), but concentrations can increase substantially-frequently reaching hundreds or thousands of pg/mL-during acute viral infections, chronic inflammatory diseases, autoimmune disorders (e.g., type 1 diabetes, multiple sclerosis, rheumatoid arthritis), transplant rejection, and certain malignancies, depending on disease severity and immune activation status. Measurement of human CXCL10 provides valuable insight into Th1-type immune activation, interferon-driven inflammatory responses, T cell trafficking, and disease progression in clinical and translational research settings. The ELISA kit contains a capture antibody, detection antibody, and recombinant human CXCL10 protein standard validated for use together in an ELISA format; kit components are not supplied in matched quantities and may be purchased separately. This product is for research use only, not for use in diagnostic or therapeutic procedures, and is manufactured in the USA.
Storage Conditions2°C to 8°C or -20°C
Country Of OriginUSA
Human CXCL10 (C-X-C motif chemokine ligand 10), also known as IP-10 (Interferon gamma–induced protein 10), is a proinflammatory chemokine belonging to the CXC chemokine family, which also includes CXCL9 (MIG) and CXCL11 (I-TAC) that regulate T-cell recruitment during antiviral and inflammatory immune responses. In humans (Homo sapiens), CXCL10 is produced by macrophages, dendritic cells, epithelial cells, endothelial cells, fibroblasts, and various tissue cells in response to interferon-γ (IFN-γ), viral infection, or inflammatory cytokines. CXCL10 signals primarily through the chemokine receptor CXCR3, which is expressed on activated T lymphocytes, natural killer (NK) cells, and other immune cells, promoting chemotaxis and activation of these cells at sites of infection or inflammation. CXCL10 plays a critical role in antiviral immunity and Th1-type immune responses, particularly in infections such as hepatitis C virus (HCV) and SARS-CoV-2, where elevated CXCL10 levels are associated with immune cell recruitment to infected tissues and inflammatory disease severity. Because dysregulated CXCL10 signaling has been linked to chronic inflammatory diseases, autoimmune disorders, and cancer-associated inflammation, human CXCL10 is widely studied in immunology, infectious disease research, and therapeutic development as both a biomarker of immune activation and a potential target for modulating inflammatory responses.

Please choose a size to see price


Reagents for Animal Model and Animal Health Research

Kingfisher Biotech, Inc.
1000 Westgate Drive
Suite 123
Saint Paul, MN 55114

Phone: 651-646-0089
Fax: 651-646-0095

Animal Antibodies

Newsletter

"